Wells Fargo & Company »

Sab Biotherapeutics shares owned by Wells Fargo & Company

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Wells Fargo & Company from 13F filings

Historical chart of Wells Fargo & Company investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Wells Fargo & Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Wells Fargo & Company

Quarter filed Position value Share count Share price at filing
2026-06-30 $172k 44k 3.90
2024-03-31 $277 61 4.54

More positions owned by Wells Fargo & Company

Apple Call Option (AAPL)
Ishares Tr Core S&p500 Etf (IVV)
Microsoft Corporation (MSFT)
NVIDIA Corporation Put Option (NVDA)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr Core S&p Ttl Stk (ITOT)
Broadcom (AVGO)
Vanguard Index Fds Mid Cap Etf (VO)
Amazon (AMZN)
Ishares Tr Core Msci Eafe (IEFA)
Ishares Tr Russell 2000 Etf Put Option (IWM)
JPMorgan Chase & Co. (JPM)
Ishares Core Msci Emkt (IEMG)

View all positions for Wells Fargo & Company

Top funds holding Sab Biotherapeutics

Caligan Partners
Vivo Capital
Perceptive Advisors
Adage Capital Partners GP
RA Capital Management
Balyasny Asset Management
BlackRock
Vanguard Capital Management
Commodore Capital
Millennium Management
Spruce Street Capital
Sessa Capital IM
Affinity Asset Advisors
Boothbay Fund Management
Geode Capital Management

View all funds holding Sab Biotherapeutics